ArticleCancer discovery2024

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

Federica Pecci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.